| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More | Alex Lash | 12/21/18 | National |
| With New Results, FibroGen’s Anemia Pill Inches Closer to FDA Review | Ben Fidler | 12/20/18 | San Francisco |
| Akebia Merges With Keryx as Anemia Drug Race Nears Finish Line | Ben Fidler | 06/28/18 | Boston |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits | Ben Fidler | 01/30/17 | San Francisco |
| As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO | Ben Fidler | 11/14/14 | San Francisco |
